Atea Pharmaceuticals, Inc. (AVIR)
| Market Cap | $318.00M+36.4% |
| Revenue (ttm) | n/a |
| Net Income | -$155.40M |
| EPS | -$1.95 |
| Shares Out | 80.30M |
| PE Ratio | n/a |
| Forward PE | -2.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 448,459 |
| Open | $4.11 |
| Previous Close | $4.12 |
| Day's Range | $3.85 - $4.18 |
| 52-Week Range | $2.92 - $6.45 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | $9.00(+127.27%) |
| Earnings Date | Nov 9, 2026 |
About AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$AVIR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in AVIR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AVIR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AVIR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
AVIR Revenue by Segment
| Stock based compensation | $3.47M | 88.74% |
| Consulting and professional fees | $440.00K | 11.26% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New AVIR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AVIR from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from AVIR’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings reported with $200M credit facility secured, indicating financial stability and operational progress.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| GERM | ETFMG Treatments, Testing and Advancements ETF | 0.66% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.29% |
| OMFS | Invesco Russell 2000 Dynamic Multifactor ETF | 0.20% |
| IWC | iShares Micro-Cap ETF | 0.07% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.02% |
| IBB | iShares Biotechnology ETF | 0.02% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.01% |
| JHMH | John Hancock Multifactor Health Care ETF | 0.01% |
| PKW | Invesco BuyBack Achievers ETF | 0.01% |
| VHT | Vanguard Health Care ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
